AIP
VRTX icon

Ahrens Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Ahrens Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$107K Buy
+340
New +$102K 0.05% 213
2022
Q3 		– Sell
-40
Closed -$11K – 894
2022
Q2 		$11K Hold
40
– – ﹤0.01% 631
2022
Q1 		$10K Hold
40
– – ﹤0.01% 740
2021
Q4 		$9K Buy
+40
New +$7.78K ﹤0.01% 776

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ahrens Investment Partners's VRTX Position: Q1 2023 in Review

Ahrens Investment Partners opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2023: 340 shares worth $107K. The stake represents 0.05% of the portfolio and ranks #213 among its holdings. This is a return to the name: Ahrens Investment Partners previously reported a position in VRTX as recently as Q2 2022.

Ahrens Investment Partners first reported a position in VRTX in Q4 2021 and has held it in 4 quarters since. 1,207 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

  • Ahrens Investment Partners held 340 shares of Vertex Pharmaceuticals worth $107K as of Q1 2023.
  • Vertex Pharmaceuticals was a new Ahrens Investment Partners position in Q1 2023.
  • Vertex Pharmaceuticals made up 0.05% of Ahrens Investment Partners's portfolio in Q1 2023, its #213 holding.
  • Ahrens Investment Partners first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
  • 1,207 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.